What happened
Laprophan listed in Casablanca and pulled in 2.22 billion dirhams, or $223 million. It priced 6.52 million shares - a mix of new and existing stock - at 341 dirhams, implying a market value around 5.9 billion dirhams.
CFG Bank Capital Markets ran the deal as lead manager. Executive director Bachir Tazi said orders topped available shares by a factor of six. Bloomberg-compiled figures indicate it is the largest pharmaceutical IPO on the continent.
How the deal stacks up
Tazi also noted the offering ranks as the second-biggest IPO by a private Moroccan company, behind last year's Societe Generale des Travaux du Maroc.
What Laprophan plans and how it looks
Founded in 1949, Laprophan intends to deploy the proceeds to buy a local competitor, expand its product range, and enter more overseas markets. For the latest year, the company posted revenue of 2.5 billion dirhams and net income of 104 million dirhams.
When new listings and developments appear, staying informed helps, so get the free Market Briefs newsletter every morning.
The backdrop for investors
Morocco's market jumped 28% in 2025, then fell roughly 8% year-to-date in 2026 as rising input costs linked to Middle East tensions, worries about credit quality, and a slowdown in tourism pressured sentiment. The World Bank sees the economy growing 4.4% this year, easing from 4.9% a year earlier. In plain English: a solid company story is listing into a choppier tape, which can mean bumpier trading even for quality issuers.
Markets can shift quickly, and a concise update makes decisions easier, so subscribe to Market Briefs for free.
